Hims & Hers Health (NYSE:HIMS) COO Michael Chi Sells 14,027 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) COO Michael Chi sold 14,027 shares of the company’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $28.39, for a total transaction of $398,226.53. Following the transaction, the chief operating officer owned 456,660 shares of the company’s stock, valued at approximately $12,964,577.40. This represents a 2.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Hims & Hers Health Price Performance

Shares of NYSE HIMS traded down $0.08 during midday trading on Thursday, reaching $27.92. 8,214,836 shares of the company were exchanged, compared to its average volume of 24,477,230. The stock’s 50-day moving average price is $30.34 and its 200-day moving average price is $27.51. The stock has a market cap of $6.51 billion, a P/E ratio of -44.32 and a beta of 2.42. Hims & Hers Health, Inc. has a one year low of $13.74 and a one year high of $65.30. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The firm had revenue of $753.21 million during the quarter, compared to the consensus estimate of $698.90 million. During the same quarter in the previous year, the company posted $0.17 earnings per share. The firm’s revenue was up 38.2% on a year-over-year basis. On average, sell-side analysts anticipate that Hims & Hers Health, Inc. will post -0.16 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

HIMS has been the topic of several recent research reports. Bank of America lifted their target price on shares of Hims & Hers Health from $30.00 to $32.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Hims & Hers Health from $25.00 to $26.00 and gave the stock a “hold” rating in a report on Tuesday, August 11th. Wall Street Zen raised Hims & Hers Health from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Weiss Ratings reiterated a “sell (d)” rating on shares of Hims & Hers Health in a research report on Friday, August 7th. Finally, Truist Financial lifted their price objective on Hims & Hers Health from $27.00 to $32.00 and gave the stock a “hold” rating in a research note on Monday, August 24th. Three equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Hims & Hers Health currently has a consensus rating of “Hold” and an average price target of $32.43.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Negative Sentiment: Multiple law firms announced or promoted a securities class action against Hims & Hers and certain executives. The proposed class covers investors who purchased shares between August 4, 2025, and July 29, 2026, with November 2, 2026, set as the lead-plaintiff deadline. ClaimsFiler shareholder alert
• Negative Sentiment: The allegations center on potentially deceptive or unlawful privacy and billing practices, including issues connected with data sharing. These claims remain allegations, but could create legal liabilities and distract management. Hagens Berman class-action announcement
• Negative Sentiment: The legal-news flow reinforces concerns already reflected in recent selling pressure, while Hims & Hers continues to report losses and has substantial balance-sheet leverage. The stock has therefore remained volatile and below its recent 50-day average.
• Neutral Sentiment: Bank of America Securities maintained a Hold rating, offering no new bullish catalyst or meaningful change to the current analyst view. Bank of America Hold rating

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its holdings in shares of Hims & Hers Health by 12.4% during the 4th quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock worth $183,485,000 after buying an additional 608,950 shares in the last quarter. Bank of America Corp DE boosted its stake in Hims & Hers Health by 194.4% during the first quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock worth $90,465,000 after acquiring an additional 2,877,550 shares in the last quarter. Norges Bank acquired a new stake in shares of Hims & Hers Health in the 4th quarter valued at about $62,153,000. Clear Street Group Inc. increased its position in Hims & Hers Health by 23.6% in the 4th quarter. Clear Street Group Inc. now owns 1,904,294 shares of the company’s stock valued at $61,832,000 after buying an additional 363,893 shares in the last quarter. Finally, State of Michigan Retirement System raised its stake in Hims & Hers Health by 13.7% during the 1st quarter. State of Michigan Retirement System now owns 2,338,600 shares of the company’s stock worth $48,549,000 after buying an additional 280,900 shares during the period. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides access to personalized care through digital platforms, including the Hims and Hers brands. The company connects consumers with licensed healthcare professionals for online consultations, treatment plans and prescription medications, where appropriate.

Its services address areas such as sexual health, hair loss, skin care, mental health, weight management and primary care. Hims & Hers also offers over-the-counter products, supplements and personal-care items, with products and prescriptions delivered directly to customers through its fulfillment network and pharmacy partners.

The company was established in 2016 and initially focused on men’s health before expanding under the Hers brand to serve women and broaden its health-care offerings.